Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995
Buy Report Download FREE Resources

Published: August 11, 2025 Report Code: GDHC326PIDR-8M-ST

Select Item

Analyze the Alzheimer’s Disease therapeutics market across eight major markets with revenue forecasts, pipeline analysis, disease-modifying therapies, competitive dynamics, unmet needs, and outlook through 2033.

Why Does the Alzheimer’s Disease Therapeutics Market Matter?

The Alzheimer’s Disease therapeutics market is entering a period of significant expansion, driven by advances in disease-modifying treatments, growing adoption of anti-Aβ monoclonal antibodies, and improvements in diagnosis.

Across the eight major markets (8MM), the market was valued at $2.4 billion in 2023 and is projected to reach $17.0 billion by 2033, representing a 21.8% CAGR.

This report provides a comprehensive view of the evolving Alzheimer’s Disease treatment landscape, combining market forecasts with epidemiology, treatment usage, pipeline analysis, clinical trial activity, competitor assessment, and emerging opportunities across the US, France, Germany, Italy, Spain, the UK, Japan, and China.

Key Insights in the Alzheimer’s Disease Therapeutics Market

The report provides insight into:

  • Alzheimer’s Disease therapeutics market size and growth
  • Revenue forecasts from 2023 to 2033
  • Symptomatic and disease-modifying treatments
  • Growth of anti-Aβ monoclonal antibody therapies
  • Market performance across the 8MM
  • Country-level market dynamics
  • Cost of therapy and treatment usage
  • Epidemiology and disease burden
  • Unmet needs across the treatment landscape
  • Clinical trial activity and its market implications
  • Pipeline products and emerging mechanisms of action
  • Promising late-stage candidates
  • Current and future competitive dynamics
  • Key market drivers, restraints, and challenges

Scope

What Will You Learn from This Alzheimer’s Disease Therapeutics Market Report?

This report provides insight into:

  • How the Alzheimer’s Disease therapeutics market is expected to evolve through 2033

  • Market revenue forecasts across the eight major markets

  • Treatment usage and cost of therapy per patient

  • The changing balance between symptomatic and disease-modifying treatments

  • The impact of emerging anti-Aβ therapies on market growth

  • Key unmet needs within Alzheimer’s treatment

  • Clinical trials shaping the future treatment landscape

  • Pipeline products and mechanisms of action under development

  • Promising late-stage candidates

  • Competitive positioning of current and future therapies

  • Market drivers, restraints, and challenges

  • Opportunities for investment, licensing, partnerships, and commercial expansion

Who Should Buy This Alzheimer’s Disease Therapeutics Market Report?

This report may be valuable for:

  • Pharmaceutical companies

  • Biopharmaceutical companies

  • Alzheimer’s Disease and CNS therapeutics developers

  • Drug developers

  • Business development teams

  • Licensing and partnering teams

  • Commercial strategy teams

  • Market intelligence functions

  • Healthcare investors

  • Strategic partnership teams

  • Healthcare consultants and industry advisors

How Companies Use This Alzheimer’s Disease Market Analysis

Companies can use the report to assess market opportunities, pipeline developments, competitive positioning, and future treatment trends.

For example:

  • Pharmaceutical companies can evaluate market growth and emerging treatment opportunities across the 8MM.

  • CNS therapeutics developers can assess the evolving competitive landscape and unmet needs.

  • Business development teams can identify pipeline products, technologies, and companies for licensing opportunities.

  • Commercial strategy teams can use market forecasts and competitor analysis to support market planning.

  • Market intelligence teams can monitor clinical trials, pipeline developments, and emerging competitors.

  • Sales and marketing teams can benchmark competitor performance and understand treatment usage patterns.

  • Investors can assess high-growth market segments and emerging therapeutic opportunities.

  • Strategic partnership teams can identify opportunities for collaboration, investment, and consolidation.

  • Consultants can use market forecasts and competitive insights to support strategic recommendations.

Reasons to Buy

Benchmark the Alzheimer’s Disease Therapeutics Market Across Eight Major Markets

The report enables users to benchmark the Alzheimer’s Disease therapeutics landscape across the US, France, Germany, Italy, Spain, the UK, Japan, and China.

Benchmarking includes:

  • Market revenue

  • Market growth

  • Treatment usage

  • Cost of therapy

  • Epidemiology

  • Competitive dynamics

  • Pipeline activity

  • Clinical trial developments

  • Late-stage candidates

  • Market drivers and restraints

  • Unmet needs

The analysis helps businesses compare market opportunities and understand how treatment landscapes differ across major healthcare systems.

Built on GlobalData Pharma Intelligence

GlobalData’s Alzheimer’s Disease Major Market Analysis combines quantitative market forecasting with epidemiology, treatment landscape analysis, pipeline intelligence, clinical trial assessment, and competitive analysis.

The report is supported by an Excel-based forecast model through 2033, providing a structured view of market revenues, treatment usage, costs, pipeline developments, and future competitive dynamics across the eight major markets.

Act Now to Identify Opportunities in the Alzheimer’s Disease Therapeutics Market

The Alzheimer’s Disease therapeutics market is entering a period of rapid transformation as disease-modifying treatments and anti-Aβ monoclonal antibodies reshape the treatment landscape.

Use GlobalData’s Alzheimer’s Disease Major Market Analysis to track market growth through 2033, assess emerging therapies and late-stage candidates, benchmark competitive dynamics, and identify opportunities for licensing, investment, partnerships, and commercial expansion.

Eli Lilly and Co
Otsuka Pharmaceutical Co Ltd
Novartis AG
Biogen Inc
Eisai Co Ltd
Suven Life Sciences Ltd
Towa Pharmaceutical Co Ltd
AB Science SA
H. Lundbeck AS
Neurimmune Holding AG
Annovis Bio Inc
Teikoku Seiyaku Co Ltd
AbbVie Inc
BioVie Inc
Alzheon Inc
Axsome Therapeutics Inc
TauRx Pharmaceuticals Ltd
Anavex Life Sciences Corp
Shanghai Green Valley Pharmaceutical Co Ltd
Johnson & Johnson
Corium LLC
Bristol-Myers Squibb Co
Ono Pharmaceutical Co Ltd
Novo Nordisk AS
Daiichi Sankyo Co Ltd
AriBio Co Ltd
Luye Pharma Group Ltd
BioXcel Therapeutics Inc
AlphaCognition Inc
Biomed Industries Inc
Cerecin Inc

Table of Contents

List of Contents

List of Tables

List of Figures

1 Alzheimer’s Disease: Executive Summary

1.1 Summary of changes

1.2 Executive summary

1.3 Alzheimer’s market forecast to see double-digit sales growth out to 2033

1.4 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2033

1.5 Opportunities to fulfil key unmet needs will remain

1.6 Novel late-stage pipeline drugs will be a key driver of growth

1.7 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology

3.1.1 Risk genes

3.1.2 Deterministic genes

3.1.3 Protective genes

3.1.4 Metabolic disruption

3.2 Pathophysiology

3.2.1 Structural changes in the brain

3.2.2 Degenerative process

3.2.3 Aβ plaques

3.2.4 Neurofibrillary tangles

3.2.5 Neurotransmitter deficiencies

3.2.6 Oxidative stress

3.3 Biomarkers / targets of interest

3.4 Disease staging systems

3.5 Symptoms and prognosis

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast assumptions and methods: total prevalent cases of AD by DSM-IV criteria

4.4.4 Forecast assumptions and methods: total prevalent cases of AD by severity

4.4.5 Forecast assumptions and methods: total prevalent cases of preclinical AD

4.4.6 Forecast assumptions and methods: total prevalent cases of MCI

4.5 Epidemiological Forecast for AD (2023-33)

4.5.1 Total prevalent cases of AD by DSM-IV criteria

4.5.2 Age-specific total prevalent cases of AD by DSM-IV criteria

4.5.3 Sex-specific total prevalent cases of AD by DSM-IV criteria

4.5.4 Total prevalent cases of AD by severity

4.5.5 Total prevalent cases of preclinical AD

4.5.6 Age-specific total prevalent cases of preclinical AD

4.5.7 Sex-specific total prevalent cases of preclinical AD

4.5.8 Total prevalent cases of MCI

4.5.9 Age-specific total prevalent cases of MCI

4.5.10 Sex-specific total prevalent cases of MCI

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More efficacious DMTs

7.3 Improved control of behavioral symptoms

7.4 Symptomatic drugs for cognition

7.5 Improving diagnosis earlier in the disease progression

7.6 Access to treatment

8 R&D Strategies

8.1 Overview

8.1.1 Targeting Aβ

8.1.2 Novel MOAs

8.1.3 Targeting agitation and psychosis

8.1.4 Targeting preclinical AD

8.1.5 Combination therapies

8.1.6 Non-pharmacological treatments

8.2 Clinical Trials Design

8.2.1 Inclusion/exclusion criteria

8.2.2 Endpoints

8.2.3 Use of biomarkers in trial design

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Potential DMTs

10.2.2 Therapies for agitation and psychosis associated with AD

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

12.5 China

12.5.1 Forecast

12.5.2 Key events

12.5.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 AD clinical development pipeline

13.4 Methodology

13.4.1 Forecasting methodology

13.5 Primary research – KOLs interviewed for this report

13.6 Primary research – prescriber survey

13.7 About the authors

13.7.1 Analyst

13.7.2 Therapy Area Director

13.7.3 Epidemiologist

13.7.4 Managing Epidemiologist

13.7.5 Vice President of Disease Intelligence and Epidemiology

13.7.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

Most Popular
$35,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Alzheimer's Disease reports
Pharmaceuticals
New
Rare Diseases: Innovation, Investment, and Unmet Needs - Strategic Intelligence
$3,450 | September 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, August 2026
$2,950 | September 2026
Pharmaceuticals
New
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…
$3,495 | September 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more